Business
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
New data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral
About this update from Anavex Life Sciences Corp.
[{"type":"text","content":"New data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI1 control group after 144 weeks (33.1 months) of treatment Oral presentation at the AD/PD™ 2026 Conference Symposium: ‘Advances in AD treatment’ highlights the convenience of oral blarcamesine for both patients and families NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced new data of blarcamesine was presented at the AD/PD™ 2026 Conference by Prof. Dr. Timo Grimmer, MD, and collaborators, titled, Advancing Alzheimer’s Disease Care: Convenience for both Patients and Families with Oral Blarcamesine with Long-term Time Saved, drawing from the ANAVEX®2-73-AD-004 (NCT03790709) Phase IIb/III clinical program and its long-term open-label extension, ANAVEX®2-73-AD-EP-004 (NCT04314934). “The patient-friendly oral administration, the manageable side effects, and the clinical efficacy—particularly in the genetically defined ABCLEAR32 population—make blarcamesine, in conjunction with the associated biomarker signal, a promising drug candidate for patients with early-stage Alzheimer’s disease,” said Prof. Dr Timo Grimmer, MD, member of the Anavex Scientific Advisory Board and National Coordinating Investigator for the blarcamesine Phase IIb/III ANAVEX®2-73-AD-004 study. “Alzheimer’s disease is a devastating chronic disease that affects millions worldwide. We believe, these new results will contribute to the growing body of scientific data demonstrating the long-term beneficial effect of blarcamesine in early Alzheimer’s disease.” Data from the ANAVEX®2-73-AD-004 study also show that patients with wild-type (WT) SIGMAR1 and COL24A1 genes, the ABCLEAR32 population, may experience substantially greater clinical and structural benefit from blarcamesine. This reinforces Anavex’s precision medicine strategy, leveraging genomic and biomarker-based indicators to optimize therapeutic efficacy.3 A dedicated analysis ...